He said the joint venture with Ivax was going faster than expected and he believed the deal would generate significant value for Mayne. Mayne struck the deal with Ivax in order to get to market quickly. Ivax already had applications for product approval in the system but had no sales and marketing network in Europe. Mayne provided the network and the active ingredient and the two will split the profits from Paxene.